Non-IgG antibodies Development for Parasitic Infection Therapy

Non-IgG antibodies have been demonstrated as critical components of innate (by activating mast cells) and adaptive immune responses that (mainly IgE subclass) can enhance host defense against parasitic infection. With professional scientists committed to antibody engineering, Creative Biolabs is professional in applying advanced platforms for non-IgG therapeutic antibodies production. Now, we can provide one-stop non-IgG development services, including antibody production, purification, modification, etc. IgE is one important class of therapeutic antibodies that we provide as promising treatments for human parasitic infection.

Brief Introduction of Parasitic Infection

Parasitic infection is an infectious disease caused or transmitted by parasites, which affect millions of people worldwide and cause tremendous suffering and death, especially in less-developed countries. It is common in places with poor sanitation and unhygienic practices, mainly in rural or developing areas of Africa, Asia, and Central and South America. People with a weakened immune system, such as those who have acquired immune deficiency syndrome (AIDS) or who take immunosuppressants, are the susceptible population for parasites, which can directly cause disease (such as Toxoplasma gondii and Plasmodium spp.) or cause disease by their toxins. The symptoms of parasitic infections vary depending on the invading organism. The major parasitic diseases infecting humans are divided into two categories: those caused by protozoans (single-celled organisms) and those caused by helminths (worms/metazoans).

Parasitic infections can usually be treated with antiparasitic drugs to eliminate parasites. Immunotherapies, including both antibody-based passive immunotherapy and antigen-based or active immunotherapy, have been researched and demonstrated to be effective on parasitic infection treatment, such as malaria, cryptosporidiosis, and leishmaniasis.

IgE Antibodies for Parasitic Infection

IgE antibodies have been associated with immunity against a range of parasitic infections in humans, as the levels of parasite-specific IgE and resistance to infection correlate positively. It is believed that IgE and its receptors evolved to help counter metazoan parasites. There are different mechanisms elucidates the protective functions of IgE.

• IgE antibodies can interact with cells that express the high-affinity IgE receptor (FcεRI) (such as mast cells, dendritic cells, basophils, and eosinophils) or the low-affinity IgE receptor (FcεRII) (including eosinophils, dendritic cells, platelets, macrophages, and B cells). The binding of parasite-specific IgE and antigen to FcεRI receptors and the IgE-dependent mast cell activation can result in the production and release of biologically active mediators that favor parasite expulsion.
• The other mechanism that is thought to contribute to parasite expulsion is antibody-dependent cellular cytotoxicity (ADCC) via IgE and/or IgG receptors.

Fig.1 Immune response against parasitic infection (including IgE production).¹

Non-IgG antibodies have attracted much attention in recent years resulting from their unique advantages. As a high-quality service provider, Creative Biolabs has been dedicated to non-IgG antibody development for many years for the sake of discovering more effective biomolecules. We are now offering a diversified portfolio of non-IgG antibody products and related one-stop services using our newly established platforms.

Advantages of Our Services:

• First-in-class technologies and experienced scientists;
• Fully customizable experimental design to meet specific demands;
• High-quality products with stronger affinity and enhanced neutralizing activity;
• Competitive price and best after-sale service.

If you are interested in our services, please do not hesitate to contact us for more details or a quote.

Reference

1. Montaner, Sergio, et al. "The role of extracellular vesicles in modulating the host immune response during parasitic infections." Frontiers in immunology 5 (2014): 433. Distributed under Open Access license CC BY 4.0, without modification.

---

• Non-IgG Therapeutic Antibodies Engineering
• Non-IgG Therapeutic Antibodies Discovery
• Production and Purification
• Non-IgG Therapeutic Antibodies Characterization
• Non-IgG Therapeutic Antibodies PK/PD Evaluation
• Developability Improvement

• IgA
• IgE
• IgM
• Assay kits

• Disease Therapy
• Clinical Diagnosis
• Non-IgG Antibody Application for Vaccine Development

• Non-IgG Antibody Related Diseases
• IgE Related Diseases
• Non-IgG Antibody Research Progress
• Non-IgG Antibody Isotypes
• Non-IgG Receptors and Interactions